Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.41 |
| ▸ | KCNJ11 | Q14654 | 9/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 4/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684016 | 1.00 | KCNQ3 (0.41) | KCNQ3KCNQ2KCNJ11BACE1JAK2 | |
| SCHEMBL4683461 | 0.81 | KCNQ3 (0.44) | KCNQ3KCNQ2BACE1 | |
| SCHEMBL4683458 | 0.81 | KCNQ3 (0.44) | KCNQ3KCNQ2BACE1 | |
| SCHEMBL4683574 | 0.81 | USP30 (0.43) | KCNJ11JAK2JAK1AR | |
| SCHEMBL4683571 | 0.81 | USP30 (0.43) | KCNJ11JAK2JAK1AR | |
| SCHEMBL4678738 | 0.78 | KMT2A (0.49) | — | |
| SCHEMBL4678743 | 0.78 | KMT2A (0.49) | — | |
| SCHEMBL19834756 | 0.74 | ADRB1 (0.37) | KCNQ3KCNQ2KCNJ11ADRB1 | |
| SCHEMBL19834757 | 0.74 | ADRB1 (0.37) | KCNQ3KCNQ2KCNJ11ADRB1 | |
| SCHEMBL4679717 | 0.73 | LMNA (0.53) | KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392655-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1392655-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| WO-2002062762-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | KCNQ3 25/4885KCNQ2 15/4885KCNJ11 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.